Hamps Bio share price hits 5% lower circuit, slips below listing price

Stock Market Today: Hamps Bio share price declined 5% in the morning trade on Friday to hit the lower circuit. Hamps Bio share price witnessed profit booking after a 5% rally on Thursday. 

Hamps Bio share price opened at ₹91.59 on the BSE on Friday, 5% lower than the previous close of ₹96.41.

The stock remains volatile after witnessing a strong listing recently. The stock listed at ₹96.9 per share on the BSE on December 20, a stellar 90% gain over the IPO price.

The stock, thereafter, extended gains to hit a high of ₹107.20 on December 24. However, Hamps Bio Share price has now hit a low of ₹91.59 and is trading below the listing price.

Hamps Bio IPO was a fixed price issue of ₹6.22 crore, comprising entirely a fresh issue of 12.20 lakh shares. Hamps Bio IPO price was set at ₹51 per share with a minimum lot size for an application being 2000 shares. 

The public offer ran between December 13, 2024, and December 17, 2024, garnering 1,057 times bids. The public issue was subscribed 1,342.04 times in the retail category.

About Hamps Bio

Hamps Bio was founded in 2007 and is involved in the marketing and sale of pharmaceutical products, including nutritional supplements, tablets, syrups, capsules, injectables, and oil. 

The business sells its goods via a network of more than 50 distributors and online marketplaces, such as Jio Mart, Flipkart, and Amazon (US, Canada, and EU). Eight states and union territories see sales of pharmaceutical products by Hamps Bio, whereas 22 states and union territories and 6 countries see supply of freeze-dried products and frozen goods. 

The company's business is divided into two segments: First is pharmaceuticals, wherein the company's products are marketed under the "Hamps" brand. The range includes tablets, syrups, capsules, injectables, and powders. The second segment is freeze-dried and frozen products.

Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.